ALT

Business Context and Reporting Period

Company: PharmAthene, Inc. (Note: Request metadata listed "Altimmune, Inc.", but the filing text identifies the registrant as PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. Its lead product candidates include SparVax (anthrax vaccine), Valortim (anthrax monoclonal antibody), and rBChE (nerve agent countermeasure). The company relies primarily on U.S. government contracts and grants for revenue.

Key Financial Metrics

Note: The filing does not provide explicit margin percentages. Operating expenses for Q1 2011 were $10.9 million, resulting in a loss from operations of $4.5 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 103% year-over-year, driven primarily by the SparVax program ($5.4M in Q1 2011 vs. $2.1M in Q1 2010). This increase was due to additional manufacturing work and the achievement of milestones totaling $1.3 million.
• Net Loss Reduction: Net loss decreased significantly to $2.1 million from $7.9 million in the prior year. This improvement was largely due to a non-cash gain of $2.5 million from the change in market value of derivative instruments (warrants), compared to a $0.3 million gain in 2010.
• Interest Expense: Interest expense dropped to $15,435 from $948,150 in Q1 2010, as outstanding convertible notes were converted to equity or redeemed in late 2010.
• Operating Expenses: Research and Development (R&D) expenses increased to $5.8 million from $5.0 million, reflecting increased activity on SparVax and the completion of the Valortim Phase I trial. General and Administrative (G&A) expenses decreased to $4.9 million from $5.3 million due to cost reduction initiatives.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates safety follow-up for the Valortim Phase I trial to be completed in Q3 2011. The company expects to continue incurring losses and will require additional financing to fund operations and R&D.
• Liquidity: Cash and cash equivalents were $9.7 million as of March 31, 2011. The company notes that future funding availability is uncertain due to market conditions and potential reductions in U.S. government biodefense spending.
• Legal Contingency (SIGA Litigation): A trial regarding a breach of contract claim against SIGA Technologies concluded in January 2011, with closing arguments in April 2011. PharmAthene seeks an exclusive license for SIGA's drug candidate ST-246 or monetary damages. If specific performance is awarded, the company may be obligated to make upfront and milestone payments between $6 million and $11 million.
• Unusual Items: The financial results were significantly impacted by the fair value adjustment of derivative liabilities (warrants), which generated a $2.5 million gain in Q1 2011 due to a decline in the company's stock price.
• Exit Activities: The company closed its Canadian production facility in Q4 2010. Assets held for sale related to this facility are expected to be sold within twelve months.

Investor Verification Checklist

• Derivative Liability Volatility: Verify the sensitivity of net income to stock price fluctuations, as the $2.5 million gain was non-cash and driven by warrant valuation.
• SIGA Litigation Outcome: Monitor the court ruling on the SIGA Technologies case, as a loss could result in significant damages, while a win for specific performance could trigger substantial cash outflows ($6M-$11M).
• Government Contract Reliance: Assess the risk of funding delays or reductions in U.S. government contracts (DoD, NIAID, BARDA), which constitute the primary revenue source.
• Cash Burn Rate: Evaluate the runway provided by the $9.7 million cash balance against the $2.1 million quarterly operating cash burn and future R&D needs.
• Valortim Trial Results: Confirm the release of unblinded results from the Phase I Valortim trial expected later in 2011.